UTHR
United Therapeutics Corporation NASDAQ Listed Jun 17, 1999$569.26
After hrs
$564.94
+0.00%
Mkt Cap $24.9B
52w Low $272.12
88.1% of range
52w High $609.35
50d MA $550.52
200d MA $459.63
P/E (TTM)
18.9x
EV/EBITDA
11.0x
P/B
3.6x
Debt/Equity
0.0x
ROE
18.8%
P/FCF
20.7x
RSI (14)
—
ATR (14)
—
Beta
0.75
50d MA
$550.52
200d MA
$459.63
Avg Volume
527.0K
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
1040 Spring Street · Silver Spring, MD 20910 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 7.00 | 6.32 | -9.7% | 596.76 | +0.4% | -4.6% | — | — | — | — | — |
| Feb 25, 2026 | TNS | 7.13 | 7.70 | +8.0% | 473.43 | +1.4% | +13.0% | +6.4% | +6.4% | +8.5% | +5.3% | — |
| Oct 29, 2025 | TNS | 6.89 | 7.16 | +3.9% | 415.34 | +0.0% | +9.6% | +9.2% | +7.2% | +5.6% | +5.3% | — |
| Jul 30, 2025 | TNS | 7.29 | 6.41 | -12.1% | 297.56 | -4.0% | -5.2% | -7.7% | -1.1% | -1.7% | +2.4% | — |
| Apr 30, 2025 | TNS | 6.29 | 6.63 | +5.4% | 300.76 | +5.4% | +0.8% | -2.3% | -2.0% | -0.7% | -1.9% | — |
| Feb 26, 2025 | TNS | 6.40 | 6.19 | -3.3% | 357.50 | -3.9% | -10.8% | -9.5% | -10.5% | -13.3% | -13.7% | — |
| Oct 30, 2024 | TNS | 6.43 | 6.39 | -0.6% | 352.80 | +1.1% | +2.4% | +6.0% | +6.0% | +6.8% | +8.5% | — |
| Jul 31, 2024 | TNS | 6.40 | 5.85 | -8.6% | 337.54 | -5.0% | -7.2% | -2.9% | -2.9% | -3.5% | -4.6% | — |
| May 1, 2024 | TNS | 5.65 | 6.17 | +9.2% | 234.33 | +3.7% | +8.9% | +10.2% | +12.0% | +11.2% | +13.6% | — |
| Feb 21, 2024 | TNS | 4.19 | 4.36 | +4.1% | 214.16 | +2.6% | +2.3% | +1.6% | +6.0% | +4.4% | +5.9% | — |
| Nov 1, 2023 | TNS | 5.04 | 5.38 | +6.7% | 222.86 | -5.0% | +0.5% | +2.4% | +0.7% | +2.4% | +3.4% | — |
| Aug 2, 2023 | TNS | 4.51 | 5.24 | +16.2% | 240.13 | +8.3% | +0.3% | -3.4% | -1.6% | -1.0% | -1.4% | — |
| May 3, 2023 | BMO | 4.52 | 4.86 | +7.5% | 228.79 | -3.8% | -4.5% | -5.7% | -6.4% | -8.0% | -8.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7 | Wells Fargo | Upgrade | Equal Weight → Overweight | $735 | $596.76 | $599.00 | +0.4% | -4.6% | — | — | — | — |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $574.77 | $576.06 | +0.2% | -0.5% | +0.5% | +0.7% | +0.5% | +1.0% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.1% | -4.0% | -4.9% | -3.9% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.1% | -4.0% | -4.9% | -3.9% |
| Mar 31 | BofA Securities | Maintains | Neutral → Neutral | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.1% | -4.0% | -4.9% | -3.9% |
| Mar 30 | TD Cowen | Maintains | Buy → Buy | — | $522.83 | $605.22 | +15.8% | +12.5% | +13.4% | +9.1% | +8.0% | +7.0% |
| Mar 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $524.28 | $529.02 | +0.9% | -0.6% | +1.4% | +3.3% | +1.6% | -0.3% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $544.71 | $539.84 | -0.9% | -2.2% | -1.6% | -1.9% | -0.9% | -2.6% |
| Mar 5 | UBS | Maintains | Buy → Buy | — | $490.21 | $490.00 | -0.0% | -1.1% | -2.5% | +7.9% | +9.3% | +11.1% |
| Feb 26 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
| Feb 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $489.69 | $495.01 | +1.1% | +2.7% | +2.9% | +0.2% | -1.3% | -1.5% |
| Nov 6 | UBS | Maintains | Buy → Buy | — | $447.45 | $448.00 | +0.1% | +1.5% | +0.3% | +1.4% | +2.6% | +3.1% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $455.32 | $451.29 | -0.9% | -0.4% | -2.2% | -3.7% | -4.0% | -1.7% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $455.32 | $451.29 | -0.9% | -0.4% | -2.2% | -3.7% | -4.0% | -1.7% |
| Oct 30 | RBC Capital | Maintains | Outperform → Outperform | — | $455.32 | $451.29 | -0.9% | -0.4% | -2.2% | -3.7% | -4.0% | -1.7% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $445.38 | $445.66 | +0.1% | -1.2% | -1.2% | -2.6% | -3.0% | -2.8% |
| Sep 29 | UBS | Maintains | Buy → Buy | — | $432.66 | $429.18 | -0.8% | -1.9% | -3.1% | +1.3% | +2.5% | +4.7% |
| Sep 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $403.80 | $404.98 | +0.3% | -1.8% | +0.3% | +0.3% | -0.2% | -1.4% |
| Sep 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $380.47 | $375.61 | -1.3% | +5.3% | +3.7% | +6.1% | +4.2% | +6.4% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $380.47 | $375.61 | -1.3% | +5.3% | +3.7% | +6.1% | +4.2% | +6.4% |
| Sep 4 | UBS | Maintains | Buy → Buy | — | $391.45 | $395.60 | +1.1% | -2.8% | +2.3% | +0.8% | +3.2% | +1.3% |
| Sep 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $404.81 | $402.61 | -0.5% | -3.3% | -6.0% | -1.1% | -2.5% | -0.2% |
| Sep 2 | BofA Securities | Maintains | Neutral → Neutral | — | $304.76 | $419.63 | +37.7% | +32.8% | +28.4% | +24.8% | +31.4% | +29.5% |
| Sep 2 | Jefferies | Maintains | Buy → Buy | — | $304.76 | $419.63 | +37.7% | +32.8% | +28.4% | +24.8% | +31.4% | +29.5% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $301.39 | $302.96 | +0.5% | +2.8% | +3.5% | +3.9% | +4.2% | +3.9% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $281.95 | $283.25 | +0.5% | -2.6% | +4.4% | +3.8% | +8.1% | +7.3% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $281.95 | $283.25 | +0.5% | -2.6% | +4.4% | +3.8% | +8.1% | +7.3% |
| Jul 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $300.56 | $300.00 | -0.2% | -0.1% | -1.7% | -1.0% | -2.4% | -0.8% |
| Jul 8 | JP Morgan | Maintains | Overweight → Overweight | — | $290.39 | $290.53 | +0.0% | +1.4% | +3.5% | +3.4% | +1.8% | +2.5% |
| Jun 30 | UBS | Maintains | Buy → Buy | — | $284.27 | $285.75 | +0.5% | +1.1% | +2.3% | +3.9% | +3.6% | +2.2% |
| Jun 11 | BofA Securities | Maintains | Neutral → Neutral | — | $281.36 | $282.01 | +0.2% | -1.7% | +1.7% | +0.7% | +2.6% | +2.0% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $294.60 | $294.52 | -0.0% | +1.4% | +0.1% | +4.2% | +4.5% | +2.3% |
| May 1 | JP Morgan | Maintains | Overweight → Overweight | — | $303.09 | $304.79 | +0.6% | -3.0% | -2.8% | -1.4% | -2.7% | +1.3% |
| May 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $303.09 | $304.79 | +0.6% | -3.0% | -2.8% | -1.4% | -2.7% | +1.3% |
| May 1 | BofA Securities | Maintains | Neutral → Neutral | — | $303.09 | $304.79 | +0.6% | -3.0% | -2.8% | -1.4% | -2.7% | +1.3% |
| Apr 25 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $296.42 | $290.31 | -2.1% | -1.7% | +0.2% | +1.5% | +2.3% | -0.9% |
| Apr 21 | JP Morgan | Maintains | Overweight → Overweight | — | $284.73 | $285.57 | +0.3% | -0.2% | +2.8% | +3.1% | +4.1% | +2.3% |
| Apr 21 | BofA Securities | Upgrade | Underperform → Neutral | — | $284.73 | $285.57 | +0.3% | -0.2% | +2.8% | +3.1% | +4.1% | +2.3% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $318.89 | $318.80 | -0.0% | +1.5% | +0.4% | -2.8% | -3.2% | -2.5% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $362.33 | $363.99 | +0.5% | +1.2% | +0.7% | +0.2% | +0.7% | -0.2% |
| Nov 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $373.97 | $375.78 | +0.5% | +0.0% | +0.8% | +2.4% | +6.3% | +7.6% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +3.5% | +4.3% | +5.9% | +10.0% |
| Oct 31 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +3.5% | +4.3% | +5.9% | +10.0% |
| Oct 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $361.40 | $362.54 | +0.3% | +3.5% | +3.5% | +4.3% | +5.9% | +10.0% |
| Oct 31 | Argus | Maintains | Buy → Buy | — | $361.40 | $362.54 | +0.3% | +3.5% | +3.5% | +4.3% | +5.9% | +10.0% |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | $368.43 | $366.99 | -0.4% | +0.6% | +0.5% | -4.3% | -5.0% | -5.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 202 | $597.54 | $121K | 45,172 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 70 | $596.19 | $42K | 45,374 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 820 | $588.51 | $483K | 45,444 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 2,970 | $587.61 | $1.7M | 46,264 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 1,689 | $586.17 | $990K | 49,234 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 994 | $585.18 | $582K | 50,923 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 1,475 | $584.07 | $862K | 51,917 | — | — |
| May 7, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | Sell | 80 | $582.86 | $47K | 53,392 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 40 | $603.82 | $24K | 40,513 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 460 | $598.21 | $275K | 40,633 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 680 | $597.47 | $406K | 41,093 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 560 | $596.05 | $334K | 41,773 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 1,513 | $595.02 | $900K | 42,333 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 346 | $594.09 | $206K | 43,846 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 101 | $591.60 | $60K | 44,272 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 320 | $590.36 | $189K | 44,373 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 410 | $589.18 | $242K | 44,693 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 470 | $588.19 | $276K | 45,103 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 805 | $586.78 | $472K | 45,573 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 927 | $585.53 | $543K | 46,378 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 873 | $584.64 | $510K | 47,305 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 796 | $583.73 | $465K | 48,178 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 159 | $582.73 | $93K | 48,974 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 296 | $581.28 | $172K | 49,133 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 384 | $580.07 | $223K | 49,429 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 120 | $579.12 | $69K | 49,813 | — | — |
| May 6, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 80 | $576.32 | $46K | 49,933 | — | — |
| May 5, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 829 | $581.68 | $482K | 40,513 | -4.62% | — |
| May 5, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 504 | $580.22 | $292K | 41,342 | -4.62% | — |
| May 5, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | Sell | 678 | $579.37 | $393K | 41,846 | -4.62% | — |
8-K · 2.02
!! High
United Therapeutics Corporation -- 8-K 2.02: Earnings Results
United Therapeutics reported first-quarter 2026 earnings on May 6, 2026, providing investors with updated financial performance and operational metrics for the period ended March 31.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Nebulized Tyvaso's positive Phase 3 results for IPF treatment validate United Therapeutics' pipeline and could drive significant revenue growth if approved, supporting stock appreciation.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new CPA executive appointment suggests improved financial controls and accounting rigor, which could enhance investor confidence and potentially support stock stability, particularly relevant for smaller-cap companies like SNBR and UTHR.
Mar 12
8-K · 1.01
!! High
United Therapeutics Corp -- 8-K 1.01: Material Agreement
United Therapeutics authorized a $2 billion share repurchase program and immediately entered into accelerated share repurchase agreements with Citibank, signaling management confidence and potentially supporting stock prices through reduced share count.
Mar 9
8-K · 7.01
! Medium
United Therapeutics Corp -- 8-K 7.01: Regulation FD Disclosure
United Therapeutics will host a webcast at 8:30 a.m. to present ADVANCE OUTCOMES trial results, potentially providing investors with significant clinical data regarding a key pipeline program.
Mar 2
8-K
Mannkind Corporation -- 8-K Filing
MannKind's Furoscix ReadyFlow Autoinjector will receive FDA review completion by July 26, 2026, potentially expanding its commercial portfolio and supporting future revenue growth if approved.
Feb 26
8-K
United Therapeutics Corp -- 8-K Filing
United Therapeutics achieved record $3.18 billion in 2025 revenues, representing 11% year-over-year growth, signaling strong commercial momentum across its product portfolio for investors.
Feb 25
Data updated apr 27, 2026 7:10am
· Source: massive.com